MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53

Raita Fukaya, Shigeki Ota, Tomonori Yaguchi, Yumi Matsuzaki, Eiji Sugihara, Hideyuki Okano, Hideyuki Saya, Yutaka Kawakami, Takeshi Kawase, Kazunari Yoshida, Masahiro Toda

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tumor-initiating cells thought to drive brain cancer are embedded in a complex heterogeneous histology. In this study, we isolated primary cells from 21 human brain tumor specimens to establish cell lines with high tumorigenic potential and to identify the molecules enabling this capability. The morphology, sphereforming ability upon expansion, and differentiation potential of all cell lines were indistinguishable in vitro. However, testing for tumorigenicity revealed two distinct cell types, brain tumor-initiating cells (BTIC) and non-BTIC. We found that macrophage migration inhibitory factor (MIF) was highly expressed in BTIC compared with non-BTIC. MIF bound directly to both wild-type and mutant p53 but regulated p53-dependent cell growth by different mechanisms, depending on glioma cell line and p53 status. MIF physically interacted with wild-type p53 in the nucleus and inhibited its transcription-dependent functions. In contrast, MIF bound to mutant p53 in the cytoplasm and abrogated transcription-independent induction of apoptosis. Furthermore, MIF knockdown inhibited BTIC-induced tumor formation in a mouse xenograft model, leading to increased overall survival. Collectively, our findings suggest that MIF regulates BTIC function through direct, intracellular inhibition of p53, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant brain cells.

Original languageEnglish
Pages (from-to)2813-2823
Number of pages11
JournalCancer Research
Volume76
Issue number9
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Neoplastic Stem Cells
Brain Neoplasms
Cell Line
Macrophage Migration-Inhibitory Factors
Heterografts
Glioma
Histology
Cytoplasm
Apoptosis
Survival
Brain
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. / Fukaya, Raita; Ota, Shigeki; Yaguchi, Tomonori; Matsuzaki, Yumi; Sugihara, Eiji; Okano, Hideyuki; Saya, Hideyuki; Kawakami, Yutaka; Kawase, Takeshi; Yoshida, Kazunari; Toda, Masahiro.

In: Cancer Research, Vol. 76, No. 9, 01.05.2016, p. 2813-2823.

Research output: Contribution to journalArticle

@article{558ff294efe74741a6447bb433337d8f,
title = "MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53",
abstract = "Tumor-initiating cells thought to drive brain cancer are embedded in a complex heterogeneous histology. In this study, we isolated primary cells from 21 human brain tumor specimens to establish cell lines with high tumorigenic potential and to identify the molecules enabling this capability. The morphology, sphereforming ability upon expansion, and differentiation potential of all cell lines were indistinguishable in vitro. However, testing for tumorigenicity revealed two distinct cell types, brain tumor-initiating cells (BTIC) and non-BTIC. We found that macrophage migration inhibitory factor (MIF) was highly expressed in BTIC compared with non-BTIC. MIF bound directly to both wild-type and mutant p53 but regulated p53-dependent cell growth by different mechanisms, depending on glioma cell line and p53 status. MIF physically interacted with wild-type p53 in the nucleus and inhibited its transcription-dependent functions. In contrast, MIF bound to mutant p53 in the cytoplasm and abrogated transcription-independent induction of apoptosis. Furthermore, MIF knockdown inhibited BTIC-induced tumor formation in a mouse xenograft model, leading to increased overall survival. Collectively, our findings suggest that MIF regulates BTIC function through direct, intracellular inhibition of p53, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant brain cells.",
author = "Raita Fukaya and Shigeki Ota and Tomonori Yaguchi and Yumi Matsuzaki and Eiji Sugihara and Hideyuki Okano and Hideyuki Saya and Yutaka Kawakami and Takeshi Kawase and Kazunari Yoshida and Masahiro Toda",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-15-1011",
language = "English",
volume = "76",
pages = "2813--2823",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53

AU - Fukaya, Raita

AU - Ota, Shigeki

AU - Yaguchi, Tomonori

AU - Matsuzaki, Yumi

AU - Sugihara, Eiji

AU - Okano, Hideyuki

AU - Saya, Hideyuki

AU - Kawakami, Yutaka

AU - Kawase, Takeshi

AU - Yoshida, Kazunari

AU - Toda, Masahiro

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Tumor-initiating cells thought to drive brain cancer are embedded in a complex heterogeneous histology. In this study, we isolated primary cells from 21 human brain tumor specimens to establish cell lines with high tumorigenic potential and to identify the molecules enabling this capability. The morphology, sphereforming ability upon expansion, and differentiation potential of all cell lines were indistinguishable in vitro. However, testing for tumorigenicity revealed two distinct cell types, brain tumor-initiating cells (BTIC) and non-BTIC. We found that macrophage migration inhibitory factor (MIF) was highly expressed in BTIC compared with non-BTIC. MIF bound directly to both wild-type and mutant p53 but regulated p53-dependent cell growth by different mechanisms, depending on glioma cell line and p53 status. MIF physically interacted with wild-type p53 in the nucleus and inhibited its transcription-dependent functions. In contrast, MIF bound to mutant p53 in the cytoplasm and abrogated transcription-independent induction of apoptosis. Furthermore, MIF knockdown inhibited BTIC-induced tumor formation in a mouse xenograft model, leading to increased overall survival. Collectively, our findings suggest that MIF regulates BTIC function through direct, intracellular inhibition of p53, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant brain cells.

AB - Tumor-initiating cells thought to drive brain cancer are embedded in a complex heterogeneous histology. In this study, we isolated primary cells from 21 human brain tumor specimens to establish cell lines with high tumorigenic potential and to identify the molecules enabling this capability. The morphology, sphereforming ability upon expansion, and differentiation potential of all cell lines were indistinguishable in vitro. However, testing for tumorigenicity revealed two distinct cell types, brain tumor-initiating cells (BTIC) and non-BTIC. We found that macrophage migration inhibitory factor (MIF) was highly expressed in BTIC compared with non-BTIC. MIF bound directly to both wild-type and mutant p53 but regulated p53-dependent cell growth by different mechanisms, depending on glioma cell line and p53 status. MIF physically interacted with wild-type p53 in the nucleus and inhibited its transcription-dependent functions. In contrast, MIF bound to mutant p53 in the cytoplasm and abrogated transcription-independent induction of apoptosis. Furthermore, MIF knockdown inhibited BTIC-induced tumor formation in a mouse xenograft model, leading to increased overall survival. Collectively, our findings suggest that MIF regulates BTIC function through direct, intracellular inhibition of p53, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant brain cells.

UR - http://www.scopus.com/inward/record.url?scp=84969674345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969674345&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1011

DO - 10.1158/0008-5472.CAN-15-1011

M3 - Article

C2 - 26980763

AN - SCOPUS:84969674345

VL - 76

SP - 2813

EP - 2823

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -